This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2004 Jul;40(1):260-3.

doi: 10.1002/hep.20294.

The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?

Michael Trauner¹

Affiliations

Affiliation

¹ Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

PMID: 15239110
DOI: 10.1002/hep.20294

Comment

The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?

Michael Trauner. Hepatology. 2004 Jul.

. 2004 Jul;40(1):260-3.

doi: 10.1002/hep.20294.

Author

Michael Trauner¹

Affiliation

¹ Laboratory of Experimental and Molecular Hepatology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

PMID: 15239110
DOI: 10.1002/hep.20294

No abstract available

PubMed Disclaimer

Comment on

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Liu Y, et al. J Clin Invest. 2003 Dec;112(11):1678-87. doi: 10.1172/JCI18945. Epub 2003 Nov 17. J Clin Invest. 2003. PMID: 14623915 Free PMC article.

Similar articles

Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
Modica S, Moschetta A. Modica S, et al. FEBS Lett. 2006 Oct 9;580(23):5492-9. doi: 10.1016/j.febslet.2006.07.082. Epub 2006 Aug 8. FEBS Lett. 2006. PMID: 16904670 Review.
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.
Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S. Mencarelli A, et al. J Immunol. 2009 Nov 15;183(10):6657-66. doi: 10.4049/jimmunol.0901347. Epub 2009 Oct 30. J Immunol. 2009. PMID: 19880446
Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P, Hierro L, Jara P, Alvarez L. Martínez-Fernández P, et al. Am J Physiol Gastrointest Liver Physiol. 2009 May;296(5):G1119-29. doi: 10.1152/ajpgi.90371.2008. Epub 2009 Feb 19. Am J Physiol Gastrointest Liver Physiol. 2009. PMID: 19228886
Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G, Pasini P, Roda A, Spampinato S. Campana G, et al. Biochem Pharmacol. 2005 Jun 15;69(12):1755-63. doi: 10.1016/j.bcp.2005.03.019. Biochem Pharmacol. 2005. PMID: 15935148
FXR: a metabolic regulator and cell protector.
Wang YD, Chen WD, Moore DD, Huang W. Wang YD, et al. Cell Res. 2008 Nov;18(11):1087-95. doi: 10.1038/cr.2008.289. Cell Res. 2008. PMID: 18825165 Review.

See all similar articles

Cited by

Impact of bile acids on the growth of human cholangiocarcinoma via FXR.
Dai J, Wang H, Shi Y, Dong Y, Zhang Y, Wang J. Dai J, et al. J Hematol Oncol. 2011 Oct 12;4:41. doi: 10.1186/1756-8722-4-41. J Hematol Oncol. 2011. PMID: 21988803 Free PMC article.
Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions.
Cossiga V, Guarino M, Capasso M, Morisco F. Cossiga V, et al. Cells. 2023 Jun 7;12(12):1576. doi: 10.3390/cells12121576. Cells. 2023. PMID: 37371045 Free PMC article. Review.
Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: A population-based nested case-control study.
Huang YJ, Wu AT, Chiou HY, Chuang MT, Meng TC, Chien LN, Yen Y. Huang YJ, et al. Oncotarget. 2017 Jan 24;8(4):6642-6651. doi: 10.18632/oncotarget.14254. Oncotarget. 2017. PMID: 28036262 Free PMC article.
Gut Microbiome and Bile Acid Interactions: Mechanistic Implications for Cholangiocarcinoma Development, Immune Resistance, and Therapy.
Wu N, Bayatpour S, Hylemon PB, Aseem SO, Brindley PJ, Zhou H. Wu N, et al. Am J Pathol. 2025 Mar;195(3):397-408. doi: 10.1016/j.ajpath.2024.11.004. Epub 2024 Dec 19. Am J Pathol. 2025. PMID: 39730075 Review.
Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.
Macias RI. Macias RI. ISRN Hepatol. 2014 Feb 16;2014:828074. doi: 10.1155/2014/828074. eCollection 2014. ISRN Hepatol. 2014. PMID: 27335842 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- The Lens - Patent Citations Database